deubiquityl
enzym
dub
class
enzym
select
remov
polypeptid
posttransl
modifi
cation
ubiquitin
number
substrat
approxim
dub
exist
human
cell
involv
key
regulatori
cellular
process
drive
mani
diseas
state
make
attract
therapeut
target
sever
aspect
dub
biolog
studi
genet
knockout
knockdown
genom
proteom
studi
howev
investig
enzym
activ
regul
requir
addit
tool
monitor
cellular
physiolog
dynam
comparison
genet
ablat
dominantneg
target
valid
pharmacolog
inhibit
often
lead
strike
discrep
activ
probe
use
profi
le
class
enzym
includ
dub
allow
function
dynam
properti
assign
individu
protein
abil
directli
monitor
dub
activ
within
nativ
biolog
system
essenti
understand
physiolog
patholog
role
individu
dub
discuss
evolut
dub
activ
probe
vitro
assay
develop
use
monitor
dub
activ
cell
anim
tissu
well
recent
progress
prospect
assess
dub
inhibit
vivo
otherwis
distinct
ubiquitinproteasom
system
multipl
essenti
biolog
role
thu
function
dysfunct
import
factor
variou
human
diseas
includ
cancer
infect
infl
ammat
neurodegener
ubiquityl
substrat
protein
fi
rst
involv
atpdepend
activ
ubiquitin
polypeptid
activ
enzym
activ
involv
coval
linkag
carboxi
terminu
ubiquitin
cystein
residu
present
form
thioester
bond
activ
ubiquitin
transfer
ubiquitinconjug
enzym
form
thioester
linkag
fi
nal
step
ligas
transfer
ubiquitin
substrat
protein
major
ligas
classifi
ed
ring
fi
nger
act
bring
substrat
enzym
close
proxim
ring
fi
nger
directli
transfer
ubiquitin
substrat
hect
domain
act
form
intermedi
thioester
linkag
ubiquitin
transfer
substrat
review
recent
third
class
ligas
intermedi
mechan
action
identifi
ed
ringinbetweenr
rbr
unusu
famili
ubiquitin
compos
dozen
protein
activ
autoinhibit
caus
requir
activ
proteinprotein
interact
posttransl
modifi
cation
catalyz
ubiquitin
conjug
concert
ringhectlik
mechan
domain
facilit
directli
form
thioester
intermedi
cystein
shortliv
hectlik
intermedi
modifi
es
target
follow
monoubiquityl
substrat
process
either
stop
form
monoadduct
ubiquitin
repeat
form
elong
chain
ubiquitin
residu
polyubiquitin
chain
form
use
nterminu
linear
seven
intern
lysin
residu
found
ubiquitin
variou
chain
topolog
lead
differ
function
outcom
well
studi
linkag
polyubiquitin
chain
often
involv
nonproteolyt
signal
transduct
chain
gener
target
substrat
proteasom
degrad
number
addit
linkag
identifi
ed
nondegrad
cellular
signal
role
still
subject
number
investig
complex
ubiquitin
chain
signal
enhanc
exist
mixedlineag
chain
protein
destin
degrad
via
ubiquitinproteasom
system
includ
protein
damag
improperli
fold
short
halfliv
protein
appropri
polyubiquityl
recogn
degrad
macromolecular
proteasom
complex
complex
consist
catalyt
core
particl
cap
end
regulatori
particl
regulatori
particl
subdivid
lid
base
compon
follow
recruit
proteasom
polyubiquityl
protein
undergo
deubiquityl
unfold
remov
ubiquitin
accomplish
deubiquityl
enzym
dub
associ
lid
ubiquitin
polypeptid
remov
substrat
protein
directli
recycl
cell
base
compon
play
key
role
unfold
substrat
protein
deliveri
deubiquityl
unfold
protein
catalyt
core
particl
consist
four
layer
ringlik
structur
outer
ring
compos
seven
subunit
inner
ring
compos
seven
subunit
subunit
exhibit
caspaselik
activ
subunit
trypsinlik
activ
subunit
chymotrypsinlik
activ
collect
degrad
protein
short
oligopeptid
well
recycl
amino
acid
ubiquitin
coval
link
mani
cellular
protein
regul
activ
stabil
local
interact
ubiquityl
revers
process
carri
oppos
activ
ubiquitin
ligas
dub
human
genom
encod
approxim
dub
fi
famili
dub
four
uch
usp
mjd
otu
belong
cystein
peptidas
class
one
jamm
belong
metallopeptidas
class
dub
shown
play
critic
role
mani
patholog
process
particularli
cancer
infecti
diseas
neurodegener
begun
attract
signifi
cant
attent
pharmaceut
industri
unlik
posttransl
modifi
cation
ubiquitin
abl
form
polymer
chain
ubiquitin
linkag
chain
well
length
chain
impact
fate
protein
modifi
ed
polym
ubiquitin
pharmacolog
modul
dub
use
multitud
approach
last
decad
seen
limit
success
date
howev
recent
progress
begin
identifi
dub
inhibitor
potenti
drug
develop
number
conceptu
technolog
obstacl
need
overcom
order
progress
genuin
dub
therapi
major
challeng
character
dub
inhibitor
develop
high
throughput
assay
monitor
ontarget
inhibit
cell
vivo
monitor
dub
target
engag
small
molecul
inhibitor
vivo
number
implic
firstli
biomark
readout
inhibit
understand
physiolog
implic
inhibit
class
enzym
usual
known
uniqu
ubiquityl
substrat
secondli
assess
select
compound
well
understand
mechan
action
inhibit
includ
durat
revers
pharmacodynam
paramet
activitybas
probe
abp
reli
design
chemic
warhead
select
react
activ
site
enzym
abp
usual
compos
reactiv
electrophil
coval
modifi
activesit
residu
report
group
allow
detect
label
enzym
see
fig
b
activ
probe
design
number
enzym
class
serin
hydrolas
metalloproteas
proteasom
oxidoreductas
epitopetag
ubiquitin
ubiquitinlik
deriv
util
varieti
assay
identifi
monitor
activ
dub
biolog
sampl
fig
ubiquitin
abp
instrument
identifi
cation
number
new
dub
includ
novel
class
dub
otu
unlik
proteolyt
enzym
optim
recognit
dub
requir
electrophil
trap
also
larg
portion
ubiquitin
chain
ubiquitin
bind
recognit
enzym
activ
site
truncat
portion
ubiquitin
usual
suffi
cient
trap
dub
addit
isopeptid
natur
coval
linkag
ubiquitin
target
protein
monitor
activ
endogen
enzym
dub
nativ
fulllength
statu
well
possibl
natur
occur
posttransl
modifi
cation
interferencealloster
regul
bind
partner
major
advantag
abp
irrevers
coval
natur
abp
toward
enzym
target
number
advantag
compar
mani
analyt
technolog
reli
weak
natur
transient
diffi
cult
captur
interact
enzym
substrat
variou
warhead
fig
employ
includ
alkyl
halid
chloroethyl
bromoethyl
bromopropyl
michael
acceptor
vinyl
methyl
ester
vme
vinyl
methyl
sulfon
vm
vinyl
phenyl
sulfon
vinyl
cyanid
recent
propargyl
pa
fi
rst
attempt
gener
activ
probe
label
dub
catalyt
site
thiol
group
describ
hidd
ploegh
colleagu
use
trypsin
catalyz
transpeptid
modifi
ubiquitin
carboxi
terminu
vinyl
sulfon
group
abl
demonstr
ubiquitin
vinyl
sulfon
label
recombin
purifi
ed
dub
also
number
yeast
dub
crude
lysat
ident
label
band
verifi
ed
use
individu
yeast
dub
mutant
strain
initi
version
ubiquitin
vinyl
sulfon
probe
label
iodin
allow
detect
number
dub
mous
tissu
well
mous
cell
lysat
studi
borodovski
et
al
describ
use
unlabel
ubiquitin
vinyl
sulfon
detect
specifi
c
dub
monitor
shift
appar
molecular
weight
sdspage
follow
immunoblot
label
effi
cientli
mammalian
cell
lysat
final
author
also
abl
identifi
novel
dub
associ
proteasom
thank
use
ubiquitin
vinyl
sulfon
fraction
immunepurifi
cation
assay
second
gener
activ
probe
thiolreact
group
ad
ubiquitin
use
inteinbas
chemic
ligat
method
reactiv
dub
depend
type
electrophil
warhead
fuse
ubiquitin
second
gener
probe
addit
use
identifi
cation
bound
dub
affi
niti
purifi
cation
mass
spectrometri
recent
abp
use
fl
uoresc
report
tag
gener
replac
initi
tag
eg
ha
allow
replac
immunoblot
procedur
fl
uoresc
imag
histor
product
ubiquitin
abp
base
trypsin
catalyz
transpeptid
modifi
ubiquitin
carboxi
terminu
vinyl
sulfon
group
base
addit
electrophil
warhead
via
inteinbas
chemic
ligat
method
recent
approach
move
toward
fullchem
synthesi
ubiquitin
abp
latest
improv
ad
advantag
allow
incorpor
modifi
ed
amino
acid
residu
posit
abp
whether
natur
addit
major
role
monitor
identifi
activ
dub
biolog
sampl
ubiquitinbas
probe
use
tool
structur
analysi
dub
number
cocryst
dub
ubiquitin
solv
case
structur
apodub
achiev
absenc
modifi
ed
ubiquitin
abp
abp
sometim
option
avail
cocrystal
dub
ubiquitin
substrat
ubiquitin
chain
limit
number
studi
demonstr
util
activ
probe
monitor
dub
activ
normal
diseas
anim
tissu
earlier
dub
activ
probe
public
mous
tissu
examin
signifi
cant
differ
profi
le
activ
dub
tissu
observ
recent
detail
studi
altun
et
al
investig
activ
dub
model
age
dietari
restrict
dramat
differ
level
activ
dub
cell
line
deriv
variou
tissu
well
primari
tissu
observ
small
number
dub
activ
monitor
activ
probe
bind
correl
malign
statu
cell
line
tissu
suggest
possibl
therapeut
window
dub
inhibitor
given
sensit
signifi
canc
techniqu
expect
increas
number
studi
take
full
advantag
ubiquitin
abp
monitor
differenti
dub
activ
patholog
versu
normal
condit
near
futur
abp
use
identifi
monitor
activ
bacteri
viral
parasit
dub
includ
herp
virida
chlamydia
trachomati
toxoplasma
gondii
plasmodium
falciparum
abp
invalu
tool
identifi
function
activ
dub
complex
sometim
rel
poor
diffi
cult
annot
organ
virus
bacteria
encod
full
complement
ubiquitin
proteasom
enzym
system
express
dub
evad
detect
protein
immun
system
otherwis
enhanc
virul
addit
sinc
dub
essenti
viral
prolifer
viral
dub
consid
possibl
therapeut
strategi
treatment
certain
viral
infect
sar
mer
mass
spectrometri
emerg
import
tool
character
variou
form
ubiquitin
initi
global
character
ubiquitinmodifi
ed
proteom
made
possibl
proteom
studi
take
advantag
monoclon
antibodi
recogn
digli
contain
isopeptid
follow
trypsin
digest
complex
cellular
lysat
ubiquitinaqua
approach
synthet
isotop
label
intern
standard
peptid
use
quantifi
branch
peptid
branch
gg
signatur
peptid
gener
trypsin
digest
ubiquitin
signal
proteom
studi
look
dub
interact
partner
also
gener
great
deal
inform
substrat
regul
function
addit
studi
evalu
function
role
dub
use
rnai
librari
gfpdub
fusion
link
dub
specifi
c
cellular
pathway
studi
inform
gener
wealth
data
biolog
role
dub
provid
limit
inform
regard
dynam
activ
profi
le
dub
abl
distinguish
catalyt
state
activ
versu
inact
dub
cellular
activ
dub
control
multipl
factor
includ
protein
interact
stoichiometr
chang
structur
protein
posttransl
modifi
cation
advantag
activ
probe
specifi
c
reactiv
catalyt
activ
dub
one
benefi
ts
abp
character
dub
inhibitor
abil
monitor
compound
select
chemic
activitybas
proteom
approach
use
hatag
ubiquitin
label
electrophil
warhead
haubvm
undertaken
character
select
two
inhibitor
either
immunoblot
quantit
mass
spectrometri
follow
treatment
cell
cell
lysat
compound
independ
studi
use
anoth
inhibitor
display
select
panel
biochem
dub
assay
also
subject
cellular
select
profi
ling
use
haubvm
follow
immunoblot
target
approach
activesit
ubiquitin
probe
haubvm
use
demonstr
inhibit
small
molecul
inhibit
proteasom
reconstitut
biochem
assay
similar
probe
approach
also
use
demonstr
gener
inhibitor
dub
cell
lysat
probe
antiha
antibodi
detect
conjug
ubiquitin
speci
studi
mention
pave
way
elucid
dub
select
profi
le
cellular
context
coverag
dubom
still
limit
technolog
improv
still
requir
increas
sensit
accur
monitor
dub
given
cell
tissu
experi
dub
proteom
studi
use
activ
probe
mainli
use
monitor
select
fi
rst
gener
dub
inhibitor
potenti
ubiquitin
abp
much
broader
inde
possibl
determin
dynam
natur
dub
inhibitor
use
abp
monitor
revers
durat
dub
inhibit
furthermor
work
far
dub
use
abp
restrict
cellular
studi
recent
progress
develop
dub
inhibitor
vivo
preclin
potenti
current
drive
tool
pharmacodynam
well
modeofact
understand
dub
inhibitor
vivo
activ
probe
base
select
inhibitor
peptidas
alreadi
develop
probe
target
proteasom
cathepsin
caspas
prove
use
vivo
imag
studi
well
diagnost
purpos
util
ubiquitin
activ
probe
identifi
character
dub
number
condit
limit
ubiquitin
inde
probe
enzym
remov
ubl
gener
exquisit
select
dub
cognat
substrat
suggest
specifi
c
probe
also
requir
ubl
peptidas
initi
approach
base
synthesi
peptid
vinyl
sulfon
harbor
variou
portion
ubiquitinlik
carboxi
terminu
suggest
truncat
ubl
abl
bind
ublspecifi
c
proteas
manner
similar
ubiquitinbas
vinyl
sulfon
polypeptid
ublbas
probe
gabarap
success
synthes
altern
classic
activ
probe
contain
full
ubiquitin
ubiquitinlik
polypeptid
base
use
small
molecul
inhibitor
label
catalyt
site
desumoyl
enzym
sentrinspecifi
c
proteas
senp
peptid
acyloxymethyl
keton
aomk
contain
larg
aromat
oacyl
group
select
coval
inhibitor
senp
modifi
ed
use
fl
uoresc
label
detect
senp
activ
biolog
sampl
similar
approach
describ
use
differ
famili
protein
glycin
fl
uoromethylketon
serv
probe
select
target
senp
convent
derivat
carboxytermin
end
ubl
electrophil
warhead
also
pursu
gener
derivat
procedur
produc
ubl
domain
chemic
activ
cterminu
format
thiol
ester
reaction
thiol
nucleophil
produc
desir
deriv
take
advantag
intein
fusion
technolog
technic
challeng
prevent
develop
fulli
synthet
ubl
abp
inde
number
reagent
alreadi
commerci
avail
variou
sourc
mechan
remov
ubl
specifi
c
enzym
yet
fulli
character
abp
certainli
play
key
role
elucid
understand
similarli
biolog
mechanist
function
number
dub
senp
remain
poorli
understood
exist
abp
novel
select
abp
serv
tool
extend
knowledg
parallel
develop
monoubiquitin
abp
number
group
also
achiev
total
semi
synthesi
diubiquitin
even
tetraubiquitin
chain
howev
incorpor
electrophil
warhead
polyubiquitin
chain
remain
problemat
intermedi
approach
gener
polyubiquitin
abp
elabor
basi
synthesi
branchedpeptid
incorpor
isopeptidelink
ubiquitin
electrophil
warhead
addit
synthesi
character
diubiquitin
probe
bear
dehydroalanin
warhead
near
isopeptid
bond
describ
final
abp
engin
diubiquitin
chain
incorpor
known
ubiquitin
linkag
success
allow
dub
ubiquitinlinkag
specifi
citi
cellular
context
address
structur
studi
dub
diubiquitin
demonstr
addit
peptid
fl
ank
ubiquityl
residu
extens
interact
dub
proxim
ubiquitin
chain
also
contribut
recognit
dub
probe
dub
select
latest
gener
probe
gener
distinct
pattern
obtain
use
monoubiquitin
abp
also
suggest
promiscu
dub
substrat
probabl
much
less
pronounc
initi
anticip
last
coupl
year
posttransl
modifi
cation
ubiquitin
especi
phosphoryl
ubiquitin
specifi
c
residu
eg
shown
play
import
role
number
cellular
process
ubiquitin
abp
bear
phosphoryl
variant
ubiquitin
gener
use
probe
select
modifi
cation
conjug
deconjug
enzym
enzym
usual
abl
toler
phosphoryl
ubiquitin
howev
number
dub
diffi
culti
recogn
modifi
ed
substrat
studi
evalu
addit
posttransl
modifi
cation
ubiquitin
methyl
acetyl
hydroxyl
phosphoryl
certainli
unravel
near
futur
correspond
abp
serv
use
tool
understand
mechanist
physiolog
role
novel
variant
ubiquitin
key
issu
face
research
involv
deciph
role
dub
cellular
context
lack
understand
direct
relev
substrat
specifi
c
dub
given
cellular
pathway
dub
well
character
substrat
eg
clearli
link
function
dub
howev
known
substrat
specifi
citi
still
rel
poor
partial
best
dub
certain
case
quit
clear
uniqu
substrat
exist
eg
dub
indiscrimin
recogn
ubiquityl
substrat
target
proteasom
ubiquitin
abp
play
critic
role
tool
monitor
dynam
activ
inhibit
dub
specifi
c
physiolog
pharmacolog
pathway
alter
problem
especi
acut
monitor
dub
activ
upon
inhibit
specifi
c
inhibitor
pharmaceut
develop
dub
inhibitor
requir
good
understand
pharmacokinet
modul
target
upon
treatment
compound
develop
abp
proteom
evalu
target
engag
current
investig
number
group
addit
higher
throughput
abpbas
strategi
also
develop
determin
dub
target
engag
cellular
context
well
tissu
eventu
clinic
sampl
evalu
fig
develop
activ
probe
dub
lag
behind
develop
probe
classic
proteas
inde
complex
recognit
site
dub
requir
bind
fulllength
ubiquitin
catalyt
site
well
challeng
character
potent
select
dub
inhibitor
hinder
product
abp
dub
howev
follow
groundbreak
evolut
cellperm
vivocompat
activitybas
imag
probe
develop
proteas
caspas
cathepsin
next
gener
probe
dub
certainli
agent
enabl
direct
visual
quantifi
cation
dub
activ
vivo
noninvas
agent
great
potenti
earli
diagnosi
well
pharmacodynam
evalu
dub
inhibit
preclin
well
clinic
set
one
attract
avenu
explor
develop
select
dub
activ
probe
base
design
coppercatalyz
clicklabel
dub
inhibitor
quenchabl
nonfl
uoresc
label
clicklabel
abp
allow
select
label
visual
enrich
activ
enzym
complex
proteom
anoth
approach
like
base
gener
noninvas
substrat
probe
bind
coval
enzym
advantag
approach
base
theoret
higher
signal
gener
contrast
coval
activ
probe
limit
stoichiometr
label
enzym
signal
proport
amount
enzym
variou
tissu
far
limit
number
report
substrat
avail
none
cell
permeabl
suitabl
vivo
applic
noninvas
permeabl
substrat
like
deriv
select
inhibitor
individu
dub
knowledg
around
select
ubiquityl
site
dub
substrat
probabl
one
promis
avenu
develop
celland
tissueperm
select
ubiquitin
abp
dub
reli
modifi
cation
select
small
molecul
inhibitor
dub
similar
approach
alreadi
achiev
preliminari
success
enzym
up
enzym
proteasom
probe
limit
step
develop
probe
dub
current
lack
potent
specifi
c
select
dub
inhibitor
avail
howev
commun
success
design
novel
gener
select
dub
inhibitor
number
abp
success
design
monitor
activ
cystein
peptidas
dub
still
gap
develop
abp
dub
metalloenzym
class
mpnjamm
number
approach
current
investig
design
abp
metallodub
certainli
aid
character
inhibitor
class
enzym
show
great
promis
therapeut
target
protein
ubiquityl
critic
control
protein
halflif
local
function
deregul
process
caus
factor
mani
diseas
develop
abp
allow
major
advanc
identifi
cation
character
cystein
dub
signifi
cant
progress
made
term
probe
design
prepar
exampl
fi
paper
publish
past
year
describ
diubiquitin
abp
underscor
import
tool
dub
research
jamm
famili
remain
diffi
cult
target
use
abp
due
catalyt
mechan
involv
coval
dubsubstr
intermedi
hope
new
approach
novel
probe
design
yield
better
tool
investig
class
metalloproteas
abp
ultim
shed
light
function
relev
dub
involv
variou
chainspecifi
c
ubiquitin
signal
continu
advanc
knowledg
dub
regul
function
cellular
context
furthermor
abp
aid
develop
character
dub
inhibitor
allow
monitor
target
engag
well
select
vivo
final
ubiquitin
abp
yet
broadli
use
one
might
expect
monitor
dub
development
patholog
evalu
provid
uniqu
dynam
assess
activ
dub
undoubtedli
becom
familiar
option
mani
research
